Such ratio significantly increased from baseline after 26 weeks of treatment with liraglutide 1.8 mg/day, indicating a reduction in liver steatosis, whereas it was unchanged in patients treated with lower doses of liraglutide, glimepiride or placebo
Retatrutide remains investigational and is not FDA approved as of July 2026
In addition, in the majority of countries where its use for weight control has been approved, for it to be prescribed, the patient must have actual health problems related to his or her weight
MeAgain helps by keeping five food logging methods, the shot log, custom notes, and the weight trend together so the week stays easy to interpret even when progress is uneven or symptoms come in waves
With Ozempic under legal fire, every prescription comes under scrutiny